Bio-Rad acquires AbD Serotec
Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products, has announced that it has purchased AbD Serotec, a division of MorphoSys, for approximately €53 million in cash.
AbD Serotec is one of the world’s leading antibody manufacturers, offering over 15,000 antibodies, kits and accessories. AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as other facilities in Germany and the US.
“We are pleased to have AbD Serotec join Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO.
“With AbD Serotec’s comprehensive catalogue of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA and cell sorting.”
Vaxxas to advance its microarray patches for COVID vaccination
Vaxxas will receive AU$3.2m from BARDA to accelerate work advancing its high-density microarray...
Global competition targets 'undruggable' cancer protein
A new global competition offering over US$500,000 in prizes aims to spur drug discovery...
SMi Systems appoints Dr Ankur Mutreja as Senior Advisor
Mutreja was previously Head of Global South Partnerships at CEPI, where he was responsible for...
